Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Aurélie Durgeau, Yasemin Virk, Stéphanie Corgnac and 1 more

Frontiers in Immunology · 2018 · Review

doi:10.3389/fimmu.2018.00014

Abstract

Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including CTLA-4 and PD-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies (mAb) have demonstrated survival benefits in numerous cancers, including melanoma and non-small-cell lung carcinoma (NSCLC). PD-1-expressing CD8+ T lymphocytes appear to play a major role in the response to these immune checkpoint inhibitors (ICI). Cytotoxic T lymphocytes (CTL) eliminate malignant cells through recognition by the T-cell receptor (TCR) of specific antigenic peptides presented on the surface of cancer cells by major histocompatibility complex class I (MHC-I)/beta-2-microglobulin (beta2m) complexes, and through killing of target cells, mainly by releasing the content of secretory lysosomes containing perforin and granzyme B. T-cell adhesion molecules and, in particular, lymphocyte-function-associated antigen-1 (LFA-1) and CD103 integrins, and their cognate ligands, respectively, intercellular adhesion molecule 1 (ICAM-1) and E-cadherin, on target cells, are involved in strengthening the interaction between CTL and tumor cells. Tumor-specific CTL have been isolated from tumor-infiltrating lymphocytes (TIL) and peripheral blood lymphocytes (PBL) of patients with varied cancers. TCRbeta-chain gene usage indicated that CTL identified in vitro selectively expanded in vivo at the tumor site compared to autologous PBL. Moreover, functional studies indicated that these CTL mediate human leukocyte antigen class I (HLA-I)-restricted cytotoxic activity toward autologous tumor cells. Several of them recognize truly tumor-specific antigens (TSA) encoded by mutated genes, also known as neoantigens, which likely play a key role in anti-tumor CD8 T-cell immunity. Accordingly, it has been shown that the presence of T lymphocytes directed toward tumor neoantigens is associated with patient response to immunotherapies, including ICI, adoptive cell transfer (ACT) and the dendritic cell-(DC)-based vaccine. These tumor-specific mutation-derived antigens open up new perspectives for development of effective second-generation therapeutic cancer vaccines.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

CD8+ T lymphocytes play a central role in immunity to cancer through their capacity to kill malignant cells upon recognition by T-cell receptor (TCR) of specific antigenic peptides presented on the surface of target cells by human leukocyte antigen class I (HLA-I)/beta-2-microglobulin (β2m) complexes. TCR and associated signaling molecules thus become clustered at the center of the T cell/tumor cell contact area, resulting in formation of a so-called immune synapse (IS) and initiation of a transduction cascade, leading to execution of cytotoxic T lymphocyte (CTL) effector functions. Major CTL activities are mediated either directly, through synaptic exocytosis of cytotoxic granules containing perforin and granzymes into the target, resulting in cancer cell destruction, or indirectly, through secretion of cytokines, including interferon (IFN)γ and tumor necrosis factor (TNF). Adhesion/costimulatory molecules, mainly lymphocyte-function-associated antigen-1 (LFA-1, CD11a/CD18 or αL/β2) and CD103 (αE/β7) integrins, on CTL play a critical role in TCR-mediated killing by interacting with their cognate ligands, intercellular adhesion molecule 1 (or CD54) and E-cadherin, respectively, and directing exocytosis of lytic granules to the cancer cell surface at the IS. NKG2D, a c-type lectin molecule expressed on activated lymphocytes, also plays an important role in the induction of T-cell-mediated cytoxicity and in CTL-dependent rejection of cancer. NKG2D ligands include major histocompatibility complex class I-related chain (MIC)A and MICB, and UL16-binding proteins 1, 2, and 3. These ligands are upregulated upon cell stress, such as tumor transformation, and are expressed by most of the cancer cells in particular those of epithelial origin.

Activation of naive CD8 T cells by antigen-presenting cells (APC) involves binding of TCR, that is associated with the CD3 complex, to specific peptide-major histocompatibility complex class I (pMHC-I) complexes and the interaction of the costimulatory molecules CD28 and CD2 with their respective ligands CD80/CD86 and LFA-3. Costimulatory receptors such as TNF receptor family member 4 (TNFRSF4 best known as OX40 or CD134) and member 9 (TNFRSF9 best known as 4-1BB or CD137) also play an important role in T-cell priming and antitumor immune responses.

Antitumor T-Cell Responses

Evidence for antitumor CD8+ T-cell immunity was provided by isolation of tumor-specific CTL from peripheral blood or tumor tissue of patients with diverse cancers, such as melanoma and lung carcinoma. The existence of a tumor-specific CTL response was further strengthened by identification of tumor-associated antigens (TAA) and detection of TAA-specific CD8+ T cells in spontaneously regressing tumors. Moreover, a correlation between tumor progression control and the infiltration rate of CD8+ T lymphocytes in the tumor was established. Efficacy of the antitumor immune response is negatively influenced by a hostile tumor microenvironment. Establishment of an immunosuppressive state within the tumor is mediated by diverse immunosuppressive factors released by cancer cells themselves, such as vascular endothelial growth factor, transforming growth factor-β (TGF-β) and indoleamine 2,3-dioxygenase, and/or by recruiting regulatory immune cells with immunosuppressive functions, such as regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSC). Indeed, a role for Treg cells in modulating tumor-specific effector T lymphocytes by producing immunosuppressive cytokines, such as IL-10 and TGF-β, consuming IL-2 or expressing the inhibitory molecule cytotoxic T-lymphocyte associated antigen (CTLA)-4, has been reported. MDSC are a heterogeneous group of myeloid progenitor cells and immature myeloid cells, including immature macrophages, granulocytes, and dendritic cells (DC), that impair T-lymphocyte functions by upregulating the expression of immune suppressive factors, such as arginase and inducible nitric oxide synthase, increasing the production of nitric oxide (NO) and reactive oxygen species, and inducing Treg cells. Moreover, it has been shown that predominant secretion of TNF by CD4+ T cells in MHC class II-expressing melanoma promotes a local immunosuppressive environment, impairing effector CD8+ T-cell functions.

While it is generally admitted that CD8+ T cells are directly involved in antitumor cytotoxic responses, the role of CD4+ T cells is more controversial. Involvement of CD4+ T cells in regulating antitumor immunity was associated with their help in priming of CD8+ T cells, through activation of APC and an increase in antigen presentation by major histocompatibility complex class I (MHC-I) molecules via secretion of cytokines such as IFNγ. More recently, it has been shown that CD4+ T-cell help optimized CTL in expression of cytotoxic effector molecules, downregulation of inhibitory receptors, and increased migration capacities. A role for the CD4+ T-cell subset in optimizing the antitumor immune response was supported by in vivo studies demonstrating that depletion of CD4+ T lymphocytes promotes tumor progression, whereas their adoptive transfer was correlated with improved tumor regression. Moreover, it has been reported that CD4+ T cells recognize most tumor-specific immunogenic mutanomes, and that vaccination with such CD4+ immunogenic mutations confers antitumor activity and broadens CTL responses in mice. Frequent recognition of neoantigens by CD4+ T cells was also observed in human melanoma. Notably, CD4+ CTL able to kill specific tumor cells have been described in several cancer types, including non-small-cell lung carcinoma (NSCLC), cutaneous T-cell lymphoma, and melanoma; for review, see Ref.. Elsewhere, TAA-specific CD4+ T-cell clones were shown to mediate HLA-II-restricted cytotoxic activity, making them attractive effectors in cancer immunotherapy. While CD4+ CTL are able to lyse target cells via the granule exocytosis pathway, they mainly use FasL- and APO2L/TRAIL-mediated pathways to kill their target cells.

Tumor Antigens Recognized by T Cells

Our fundamental knowledge of the tumor-specific T-cell response came with the discovery of tumor antigens that differentiated malignant cells from their non-transformed counterparts and provided important input in the field of tumor immunology and cancer immunotherapy. The first human tumor antigen recognized by CTL was identified in melanoma and was designated melanoma-associated antigen (MAGE)-1. Subsequently, several other antigens of the MAGE family were characterized, most of which were identified through generation of tumor cell lines and isolation of reactive autologous CTL clones. Based on their expression profile, tumor antigens were initially classified into two categories: TAA and tumor-specific antigens (TSA). TAA are relatively restricted to tumor cells, and, to a limited degree, to normal tissues, whereas TSA are expressed only in tumor cells, arising from mutations that result in novel abnormal protein production.

At present, numerous TAA have been identified in a large variety of human cancer types. They are heterogeneous in nature and were classified into at least four groups according to their expression repertoire and the source of the antigen: antigens encoded by cancer-germline genes, differentiation antigens, overexpressed antigens, and viral antigens (Table 1). Antigens encoded by cancer-germline genes are expressed in tumor cells and in cells from adult reproductive tissues, including placenta and testicular cells, and are thus designated cancer testis antigens. Differentiation antigens are expressed only in tumor cells and in the normal tissue of origin, while overexpressed antigens are derived from proteins that are overexpressed in tumors, but are expressed at much lower levels in normal tissues. Viral antigens derive from viral infection and are associated with several human cancers, including cervical carcinoma, hepatocarcinoma, nasopharyngeal carcinoma, and adult T-cell leukemia.

The first mutant TSA, also termed neoantigens, were identified by the genetic method via isolation of reactive CD8+ and CD4+ T-cell clones (Table 2). Recent accessibility to next-generation sequencing (NGS) technology and improvement in in silico epitope prediction have contributed to identification of patient-specific tumor antigens generated by somatic mutations in individual tumors (Table 3). Notably, most mutations identified in tumor-expressed genes do not generate neoantigens recognized by cognate T lymphocytes. Moreover, a large fraction of these mutations are not shared between patients and may thus be considered patient specific. These neoantigens have opened up new perspectives in cancer immunotherapy. They were shown to be involved in the success of immune checkpoint inhibitor (ICI), adoptive cell transfer (ACT) immunotherapy, and even virally induced epithelial cancer and DC-based immunotherapy; thus, they might be of use as predictive biomarkers of the response to immunotherapy.

Processing of CD8 T-Cell Epitopes

Most antigenic peptides recognized by CD8+ T cells originate from degradation of intracellular proteins by proteasomes and translocation to the lumen of the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP)1/TAP2 heterodimeric complex. Once in the ER, peptides larger than 11 residues are further cleaved by ER amino-peptidase (ERAP)1 and ERAP2 before being loaded onto MHC-I molecules and presented on the surface of target cells for CD8 T-cell recognition [for review, see Ref.].

Defects in the antigen-processing machinery and, in particular, in TAP subunits, have been described as a major mechanism used by several tumors to escape from CD8 T-cell immunity. In this context, alternative peptide degradation pathways permitting CD8 T cells to overcome this tumor evasion mechanism have been identified. Indeed, proteasome/TAP-independent CTL epitopes, generated either by the cytosolic metallopeptidase insulin-degrading enzyme or cytosolic endopeptidases nardilysin and thimet oligopeptidase, have been described. Moreover, TAP-independent processing of antigenic peptides can be achieved by the so-called secretory pathway in which the proteolytic enzyme furine releases C-terminal peptides. Interestingly, peptide epitopes that emerge at the surface of cancer cells with impaired TAP function derived from self-antigens and act as immunogenic neoantigens, as they are not presented by normal cells. Our group identified a signal peptide-derived CD8 T-cell epitope processed independently of proteasomes/TAP, by a novel pathway involving signal peptidase and the signal peptide peptidase. These signal sequence-derived peptides represent attractive T-cell targets that permit CTL to destroy TAP-impaired tumors and therefore correspond to promising candidates for cancer immunotherapy.

The TCR Repertoire and Antitumor T-Cell Immunity

The TCR–CD3 complex, expressed on the T-cell surface, allows recognition of antigenic peptides bound to MHC molecules on target cells and APC, and transduction of the signal into the cytosol to initiate signaling events leading to T-cell activation. The TCRα- and β-chains are products of V(D)J recombination, a somatic rearrangement of the germline TCR loci occurring in T cells. This process leads to generation of a diverse TCR repertoire [>1015 distinct αβ-receptors or clonotypes] that enables T-cell recognition of numerous foreign or mutant antigens. The TCRα- and β-chains possess three hypervariable regions, referred to as complementarity-determining regions (CDR) 1, 2, and 3. CDR3 is highly polymorphic and is directly responsible for recognition of antigenic peptides. Immunoscope/spectratype technology was first used to probe the T-cell repertoire by analyzing the diversity of TCRVβ and, more recently, TCRVα chains without isolating peptide-reactive T cells and cloning TCR genes. It is based on the use of V and J gene-segment-specific primers for reverse transcription-polymerase chain reaction amplification of CDR3 of a bulk T-cell population from diverse biological materials such as blood and tumor tissues. Analyzing CDR3 polymorphisms and sequence length diversity served to follow up T-cell clonality in tumor-infiltrating lymphocytes (TIL) to investigate T-cell functions and the pattern of TCR utilization. It highlighted restriction of the CDR3 length of TCRβ- and TCRα-chains in T cells infiltrating solid tumors and hematological malignancies, including melanoma, renal cell carcinoma (RCC), neuroblastoma, NSCLC, and Sezary syndrome. TCRβ-chain gene usage also showed that antigen-specific T-cell clones with high functional avidity/tumor reactivity expanded only at the tumor site, but not in peripheral blood. Identification of TAA has led to improvement in procedures for detecting and monitoring specific antitumor T-cell responses. In this regard, combining a quantitative immunoscope approach with MHC–peptide multimer-based T-cell sorting led to more sensitive ex vivo follow-up, by quantitation of human CD8+ T-cell responses and monitoring of T-cell subsets throughout immunotherapy clinical trials.

Tremendous progress in characterizing the size and dynamics of the T-cell repertoire has emerged from recent advances in DNA and RNA sequencing (RNAseq) technologies. High-throughput TCR sequencing (TCR-seq) involves NGS for generating DNA sequences covering TCR CDR3 and permits quantification of T-cell diversity at very high resolution. Another method for profiling the TCR repertoire relies on a TCR-specific short read assembly strategy based on 5′ amplification of cDNA ends (RACE), so as to obtain TCRβ CDR3 transcript sequences and massively parallel Illumina sequencing of TCRβ CDR3 amplification products. This strategy avoids potential bias associated with the use of multiple primer sets required to amplify CDR3 regions from all TCRBV sequences and takes advantage of the conserved sequences of TCRBC1 and TCRBC2 genes. High-throughput DNA-based strategy for identifying antigen-specific TCR sequences was also developed by the capture and sequencing of genomic DNA fragments encoding TCR genes. More recently, an optimized approach to characterizing tissue-resident T-cell (TRM) populations emerged from extraction of TCR CDR3 sequence information directly from RNAseq data sets of thousands of solid tumors and control tissues. This method circumvents the need for PCR amplification and provides TCR information in the context of global gene expression profiles.

Sequence-based immunoprofiling is a useful tool for monitoring the dynamics of the T-cell repertoire under physiological and pathological conditions, and in response to therapeutic interventions. In this respect, characterization of the TCR repertoire in TIL permits isolation of tumor-specific T-cell clones for use in cancer immunotherapy. TCR-seq can also be used to evaluate T-cell diversity and identify tumor-reactive T-cell clonotypes, along with potentially immunogenic neoantigen-reactive T cells. For instance, deep cDNA sequencing of TCR-α and β-chains enabled quantitative monitoring of the T-cell repertoire in lung cancer patients treated with cancer peptide vaccines. Another interesting parameter for follow-up by deep TCR-seq is the heterogeneity of T-cell density and clonality across tumor regions. Indeed, it has been shown that high intratumor heterogeneity of TCR is positively correlated with that of predicted neoantigens and has been associated with increased risk of disease progression. In contrast, maintenance of high-frequency TCR clonotypes alongside CTLA-4 blockade therapy was associated with improved overall survival in prostate cancer and melanoma. Moreover, high TCR clonality was associated with an increased response by melanoma patients to the programmed cell death (PD)-1 blockade, suggesting that TCR repertoire analysis could be used as a predictive marker in cancer immunotherapy. Indeed, elevated TCR clonality and significant T-cell clone expansion were observed in melanoma patients responding to anti-PD1 treatment. Overall, T-cell clonality and TCR repertoire diversity appear to be biomarkers of antitumor adaptive immunity and might also be predictive markers of responses to cancer immunotherapy.

T-Cell-Based Cancer Immunotherapies

An understanding of regulation of the molecular interaction between T cells and tumor cells, together with refined T-cell engineering technologies and the discovery of TSA, gave rise to novel cancer immunotherapies with unprecedented clinical efficacy. These therapies are aimed at (re)activating and expanding tumor-specific CTL, with the goal of destroying primary cancer cells and metastases. The most effective current cancer immunotherapies include ICI, such as anti-PD-1 and anti-CTLA-4, ACT of ex vivo-expanded tumor-reactive T cells, either native (CTL clones or TIL) or engineered to express particular TCR or chimeric antigen receptors (CAR), and TSA-based cancer vaccines (peptide- or RNA-based). Moreover, increasing evidence of a link between CD8 and CD4 T-cell recognition of mutant neoepitopes and clinical responses to cancer immunotherapy strategies has been reported; for review, see Ref..

ACT Immunotherapy

The possibility of expanding subsets of mature T cells in vitro led to development of ACT immunotherapy. The aim is to transfer a T-cell population enriched in potentially highly tumor-reactive effector cells. In this context, re-infusion of ex vivo-expanded TIL displaying increased specificity toward cancer cells was developed as a means of strengthening patient spontaneous T-cell responses and overcoming tolerance to the tumor. Steven Rosenberg’s team has been one of the pioneers in the development of ACT, mainly using selected tumor-reactive T cells and TIL. Thus, clonal repopulation of T cells directed against overexpressed self-derived differentiation antigens, in combination with chemotherapy and high doses of IL-2, led to tumor regression in patients with metastatic melanoma. Similarly, treatment of patients with uveal melanoma by adoptive transfer of autologous TIL, administered together with IL-2, resulted in objective tumor regression. Clinical responses were associated with the presence of tumor-resident CD8+ T lymphocytes that target tumor-specific mutant neoantigens and express the PD-1 checkpoint receptor. Moreover, neoantigen-reactive TCR have been identified from the most frequent clonotypes among TIL, opening up new avenues for developing a personalized TCR-gene therapy approach that targets individual sets of antigens presented by tumor cells without the need for determining their identity. Accordingly, neoantigen-reactive TCR have been identified, with the aim of treating patients with autologous T cells genetically modified to express such TCR. Nevertheless, analyses of neoantigen-specific T-cell responses in melanoma patients treated by ACT demonstrated that the T-cell-recognized neoantigens can be selectively lost over time emphasizing the importance of targeting broad TCR recognized neoantigens to avoid tumor resistance.

While ACT of tumor-specific T cells holds promise for melanoma treatment, significant challenges remain in clinical translation to other solid tumors. This can be explained by the observation that some tumors, referred to as “immune-desert tumors” or “cold tumors,” are rarely infiltrated by T cells, and TIL often display an exhausted state acquired in the tumor microenvironment. Indeed, TIL are characterized by high expression levels of one or several inhibitory receptors such as PD-1, CTLA-4, Tim-3, LAG-3, and TIGIT, and often display altered production of cytokines leading to weak antitumor reactivity; for review, see Ref.. Moreover, the limited life span of TIL and difficulties linked to their production, including isolation from fresh patient tumor specimens and selection based on tumor-specificity, constrain their clinical routine use.

To overcome limitations of TIL-based ACT, and due to the availability of TAA-specific TCR or antibodies, genetically engineered T cells have been developed with either tumor-specific TCR or CAR. Therefore, desired specificity was achieved by genetically modifying T cells to express a TAA-specific TCR. Candidates are selected either from the native TCR repertoire or after mutagenesis of their antigen recognition domain, the CDR3 domain, to increase the affinity of T cells. Thus, T cells engineered to express TAA-specific TCR (recognizing Melan-A/MART1-, gp100-, NY-ESO-, or p53-derived peptides) resulted in objective regression of metastatic melanoma lesions in some patients. As an alternative, engineered T-cell strategy utilizes CAR comprising the antigen-binding domain of an antibody, fused with one or more immunostimulatory domains, to activate T cells once the recognition domain has bound to a target cell. Because such T cells are able to recognize tumor antigen-expressing cells in a MHC-independent manner, a single CAR can be used on all patients whose tumor expresses the target antigen (i.e., CD19, CD20). The therapeutic potential of CAR-expressing T cells, especially in patients with hematological malignancies such as B-cell lymphoma expressing CD19 or CD20, has been demonstrated in several clinical trials. This holds promise for further use in hematological tumors and for treatment of solid tumors unresponsive to other immunotherapies.

Immune Checkpoint Blockade Immunotherapy

Targeting immune checkpoints with blocking monoclonal antibodies (mAb) such as anti-CTLA-4 and anti-PD-1 or anti-PD-L1 has provided clinical benefits for patients with advanced metastatic melanoma, NSCLC, RCC, and several other cancers. While the CTLA-4 blockade reduces the activation threshold required for T-cell priming, the PD1/PD-L1 blockade in certain T-cell subpopulations at least partly reverses immune alterations such as exhaustion. This allows synergy for combined treatments and opens up new perspectives for combining these checkpoint blockers (i.e., anti-CTLA-4, -PD-1, or -PD-L1) with mAb toward additional inhibitory molecules, such as BTLA, TIM-3, or LAG-3. In this regard, synergistic antitumor effects were obtained in several preclinical models.

Accumulating evidence indicates that preexisting antitumor CD8+ T cells predict the efficacy of ICI therapy. Moreover, effective CTLA-4 and PD-1 blockade immunotherapy appears to be associated with the presence of T cells directed toward mutant cancer neoepitopes, and with the likelihood of MHC presentation of these neoantigens and subsequent recognition by specific T cells. Mutant neoantigens are highly immunogenic; they are not expressed by normal tissues and thus bypass thymic tolerance. Unfortunately, clinical trials demonstrated that only a fraction of cancer patients respond to such immunotherapy. Resistance to anti-PD-1 of tumors with a high mutational load was associated with defects in pathways involved in IFNγ-receptor signaling and antigen presentation by MHC-I molecules, concomitant with a truncating mutation in the gene encoding β2m. Moreover, patients identified as non-responders to anti-CTLA-4 mAb had tumors with genomic defects in IFN-γ pathway genes. These findings demonstrate the importance of the IFN-γ signaling pathway and CD8 T-cell recognition of mutant neoantigens in response to checkpoint blockade immunotherapy.

Therapeutic Cancer Vaccines

The discovery of TAA has led to development of therapeutic cancer vaccines, based on either synthetic peptides, “naked” DNA, DC, or recombinant viruses, that attempt to strengthen the antitumor immune response, and particularly tumor antigen-specific CTL response. Peptide vaccines have many advantages, including inexpensive, convenient acquisition of clinical-grade peptides, easy administration, higher specificity, and potency due to their higher compatibility with targeted proteins, the ability to penetrate the cell membrane and improved safety with few side effects. Mechanisms underlying priming of anticancer immune responses by peptide-based vaccines, and hence their efficacy, is dependent, at least in part, on the size of the peptides. While short peptides (8–11 aa) bind directly to HLA-I molecules and mount MHC-I-restricted antigen-specific CD8+ T-cell immunity, long synthetic peptides (25–50 aa) must be taken up, processed, and presented by APC to elicit a T-cell response. Vaccination with long peptides usually results in broader immunity than with short peptides, along with induction of both CD8+ cytotoxic and CD4+ helper T cells when conjugated with efficient adjuvants. Indeed, CD4+ T-cell help is required for generation of potent CTL and long-lived memory CD8+ T cells.

First-generation cancer vaccines based on non-mutant TAA, also termed shared antigens because they are expressed by many patients’ tumors, such as MART-1, gp100, tyrosinase, TRP-2, NY-ESO-1, MAGE-A3, and Her2/neu or telomerase proteins, were shown to be immunogenic and capable of inducing clinical responses in only a minority of patients with late-stage cancer. However, results showing that CD4+ T cells directed toward NY-ESO-1 cancer-germline TAA and lymphocytes genetically engineered with a NY-ESO-1-reactive TCR display antitumor activity support the notion that T-cell responses to a subset of non-mutant antigens contribute to the effects of current cancer immunotherapies. The limited success of these active immunotherapy approaches might be due to the inability of effector T cells to overcome tolerance to self-antigens, expression of T-cell inhibitory receptors such as CTLA-4 and PD-1, and suboptimal activation of tumor-specific T cells in an immunosuppressive tumor microenvironment.

The current challenge in developing more efficient second-generation cancer vaccines is based on mutant epitopes that derive from tumor neoantigens. Non-mutant tumor neoepitopes that emerge on the target cell surface upon alteration of TAP expression, such as the self-epitope derived from the human ppCT preprohormone, are interesting targets for peptide-based vaccination against immune-escaped tumors expressing low levels of pMHC-I complexes. Recent technological advances in identifying mutation-derived tumor antigens have enabled development of patient-specific therapeutic vaccines, including peptides, proteins, DC, tumor cells, and viral vectors, that target individual cancer mutations. Over the past few years, examples of TSA-based personalized cancer immunotherapies have begun to emerge. For example, a durable clinical response to cancer vaccines with autologous melanoma-pulsed DC was obtained and correlated with the presence of effector memory T cells responding to mutant antigens. Moreover, DC-based vaccination directed at melanoma-neoepitope candidates resulted in an increase in clonal diversity of antitumor T-cell immunity and promoted a diverse neoantigen-specific TCR repertoire. Immunogenic personal neoantigen vaccines, based either on RNA or synthesized long peptides, have recently been developed for patients with melanoma. In this regard, personalized RNA-based mutanome vaccines, alone or in combination with anti-PD-1, induced effective T-cell responses against multiple vaccine neoepitopes and resulted in sustained progression-free survival. In another clinical trial, long peptide cancer vaccines that target predicted personal tumor neoantigens, administered alone or in combination with anti-PD-1, resulted in clinical benefits and induced polyfunctional CD4+ and CD8+ T cells, with expansion of the repertoire of neoantigen-specific T cells. Thus, a combination of neoepitope-based vaccines and ICI is promising for overcoming the anergic state of vaccine-induced T cells. These strategies open up new avenues for further development of personalized active immunotherapy, either alone or in combination with other therapies, for patients with different types of cancer (Figure 1). Personalized cancer immunotherapies offer promise of low toxicity and high specificity, and the opportunity to treat human malignancies resistant to current therapies.

Concluding Remarks

The success of cancer immunotherapy relies on the induction of immune effector mechanisms associated with generation of high-avidity tumor-specific CTL. To further improve their antitumor effectiveness, and for more robust long-term disease control, a deeper understanding of host-tumor interactions and tumor immune escape strategies is required. Overcoming immune tolerance/suppression pathways within the tumor microenvironment, which may hinder the potency of immunotherapeutic approaches, is a major challenge in the field of tumor immunology and immunotherapy. In this context, optimizing the therapeutic potential of the immune system relies on a combination of different approaches, mainly cancer vaccines with ICI and/or ACT, which synergistically enhance antitumor T-cell responses. Selection of the right adjuvant or neoadjuvant, such as TLR agonists, is necessary to improve the immunogenicity of peptide-based vaccines, by targeting antigens to competent APC (and, in particular, DC, capable of cross-presentation and delivering of stimuli to activate both specific CD4+ and CD8+ T cells). Moreover, alternative routes of peptide administration for improved target delivery would help to induce strong long-lasting antitumor T-cell responses and thus improve clinical outcome. Therapeutic cancer vaccines combining both TAP-dependent and TAP-independent epitopes might also boost tumor-specific CD8 T-cell immunity, prevent immune escape mechanisms developed by malignant cells, and thereby potentiate current cancer immunotherapies. Remarkably, targeting of non-self tumor-specific neoantigens, generated by somatic mutations, has gained increasing interest over the past few years. Rising accessibility to NGS technologies, improved in silico prediction of truly immunogenic mutant peptides and easy peptide manufacturing are promising approaches to identifying patient-specific neoepitopes and evaluating their potential use in both prognosis and treatment. The utility of highly immunogenic neoantigens for personalizing therapeutic cancer vaccines will open up new perspectives for the refinement of current cancer immunotherapies.

Author Contributions

FMC, AD, and SC: design and writing. YV: writing.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 196

  1. 1.

    Bossi G Trambas C Booth S Clark R Stinchcombe J Griffiths GM. The secretory synapse: the secrets of a serial killer. Immunol Rev (2002 ) 189:152–60.

    Not in our library10.1034/j.1600-065x.2002.18913.x

  2. 2.

    Anikeeva N Somersalo K Sims TN Thomas VK Dustin ML Sykulev Y. Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (2005 ) 102(18):6437–42.

    Not in our library10.1073/pnas.0502467102

  3. 3.

    Le Floc’h A Jalil A Vergnon I Le Maux Chansac B Lazar V Bismuth G Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007 ) 204(3):559–70.

    Not in our library10.1084/jem.20061524

  4. 4.

    Eichler W Ruschpler P Wobus M Drossler K Differentially induced expression of C-type lectins in activated lymphocytes. J Cell Biochem Suppl (2001 ) Suppl 36:201–8.

    Not in our library10.1002/jcb.1107

  5. 5.

    Eagle RA Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol (2007 ) 7(9):737–44.

    Not in our library10.1038/nri2144

  6. 6.

    Maccalli C Nonaka D Piris A Pende D Rivoltini L Castelli C NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res (2007 ) 13(24):7459–68.

    Not in our library10.1158/1078-0432.ccr-07-1166

  7. 7.

    Wang E Selleri S Marincola FM The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. Clin Cancer Res (2007 ) 13(24):7228–31.

    Not in our library10.1158/1078-0432.ccr-07-2150

  8. 8.

    Cerwenka A Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev (2001 ) 181:158–69.

    Not in our library10.1034/j.1600-065x.2001.1810113.x

  9. 9.

    Cosman D Mullberg J Sutherland CL Chin W Armitage R Fanslow W ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001 ) 14(2):123–33.

    Not in our library10.1016/s1074-7613(01)00095-4

  10. 10.

    Moretta A Bottino C Vitale M Pende D Cantoni C Mingari MC Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001 ) 19:197–223.

    Not in our library10.1146/annurev.immunol.19.1.197

  11. 11.

    Groh V Rhinehart R Secrist H Bauer S Grabstein KH Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999 ) 96(12):6879–84.

    Not in our library10.1073/pnas.96.12.6879

  12. 12.

    Davis SJ Ikemizu S Evans EJ Fugger L Bakker TR van der Merwe PA. The nature of molecular recognition by T cells. Nat Immunol (2003 ) 4(3):217–24.

    Not in our library10.1038/ni0303-217

  13. 13.

    Melero I Shuford WW Newby SA Aruffo A Ledbetter JA Hellstrom KE Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997 ) 3(6):682–5.

    Not in our library10.1038/nm0697-682

  14. 14.

    Sugamura K Ishii N Weinberg AD Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004 ) 4(6):420–31.

    Not in our library10.1038/nri1371

  15. 15.

    Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009 ) 9(4):271–85.

    Not in our library10.1038/nri2526

  16. 16.

    Ye Q Song DG Powell DJ Jr. Finding a needle in a haystack: activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients. Oncoimmunology (2013 ) 2(12):e27184.

    Not in our library10.4161/onci.27184

  17. 17.

    Adler AJ Vella AT. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology (2013 ) 2(1):e22837.

    Not in our library10.4161/onci.22837

  18. 18.

    Boon T Coulie PG Van den Eynde B Tumor antigens recognized by T cells. Immunol Today (1997 ) 18(6):267–8.

    Not in our library10.1016/s0167-5699(97)80020-5

  19. 19.

    Echchakir H Vergnon I Dorothee G Grunenwald D Chouaib S Mami-Chouaib F. Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. Int Immunol (2000 ) 12(4):537–46.

    Not in our library10.1093/intimm/12.4.537

  20. 20.

    Karanikas V Colau D Baurain JF Chiari R Thonnard J Gutierrez-Roelens I High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res (2001 ) 61(9):3718–24.

    Not in our library

  21. 21.

    Slingluff CL Jr Cox AL Stover JM Jr Moore MM Hunt DF Engelhard VH. Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res (1994 ) 54(10):2731–7.

    Not in our library

  22. 22.

    Weynants P Thonnard J Marchand M Delos M Boon T Coulie PG. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am J Respir Crit Care Med (1999 ) 159(1):55–62.

    Not in our library10.1164/ajrccm.159.1.9805073

  23. 23.

    Pages F Berger A Camus M Sanchez-Cabo F Costes A Molidor R Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005 ) 353(25):2654–66.

    Not in our library10.1056/nejmoa051424

  24. 24.

    Gajewski TF Meng Y Harlin H. Immune suppression in the tumor microenvironment. J Immunother (2006 ) 29(3):233–40.

    Not in our library10.1097/01.cji.0000199193.29048.56

  25. 25.

    Piccirillo CA Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol (2001 ) 167(3):1137–40.

    Not in our library10.4049/jimmunol.167.3.1137

  26. 26.

    Wing K Yamaguchi T Sakaguchi S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol (2011 ) 32(9):428–33.

    Not in our library10.1016/j.it.2011.06.002

  27. 27.

    Gabrilovich DI Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009 ) 9(3):162–74.

    Not in our library10.1038/nri2506

  28. 28.

    Donia M Andersen R Kjeldsen JW Fagone P Munir S Nicoletti F Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4+ T-cells, which dampen CD8+ T-cell antitumor reactivity. Cancer Res (2015 ) 75(18):3747–59.

    Not in our library10.1158/0008-5472.can-14-2956

  29. 29.

    Pardoll DM Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998 ) 10(5):588–94.

    Not in our library10.1016/s0952-7915(98)80228-8

  30. 30.

    Kalams SA Walker BD The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med (1998 ) 188(12):2199–204.

    Not in our library10.1084/jem.188.12.2199

  31. 31.

    Ahrends T Spanjaard A Pilzecker B Babala N Bovens A Xiao Y CD4+ T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity (2017 ) 47(5):848–61.e5.

    Not in our library10.1016/j.immuni.2017.10.009

  32. 32.

    Martorelli D Muraro E Merlo A Turrini R Rosato A Dolcetti R. Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol (2010 ) 29(4):371–402.

    Not in our library10.3109/08830185.2010.489658

  33. 33.

    Kreiter S Vormehr M van de Roemer N Diken M Lower M Diekmann J Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015 ) 520(7549):692–6.

    Not in our library10.1038/nature14426

  34. 34.

    Linnemann C van Buuren MM Bies L Verdegaal EM Schotte R Calis JJ High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med (2015 ) 21(1):81–5.

    Not in our library10.1038/nm.3773

  35. 35.

    Dorothee G Vergnon I Menez J Echchakir H Grunenwald D Kubin M Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol (2002 ) 169(2):809–17.

    Not in our library10.4049/jimmunol.169.2.809

  36. 36.

    Echchakir H Bagot M Dorothee G Martinvalet D Le Gouvello S Boumsell L Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol (2000 ) 115(1):74–80.

    Not in our library10.1046/j.1523-1747.2000.00995.x

  37. 37.

    Darrow TL Abdel-Wahab Z Quinn-Allen MA Seigler HF. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. Cell Immunol (1996 ) 172(1):52–9.

    Not in our library10.1006/cimm.1996.0214

  38. 38.

    Zennadi R Abdel-Wahab Z Seigler HF Darrow TL. Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. Cell Immunol (2001 ) 210(2):96–105.

    Not in our library10.1006/cimm.2001.1809

  39. 39.

    Huarte E Karbach J Gnjatic S Bender A Jager D Arand M HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. Cancer Immun (2004 ) 4:15.

    Not in our library

  40. 40.

    Hunder NN Wallen H Cao J Hendricks DW Reilly JZ Rodmyre R Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008 ) 358(25):2698–703.

    Not in our library10.1056/nejmoa0800251

  41. 41.

    Yasukawa M Ohminami H Yakushijin Y Arai J Hasegawa A Ishida Y Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells. J Immunol (1999 ) 162(10):6100–6.

    Not in our library

  42. 42.

    Appay V Zaunders JJ Papagno L Sutton J Jaramillo A Waters A Characterization of CD4(+) CTLs ex vivo. J Immunol (2002 ) 168(11):5954–8.

    Not in our library10.4049/jimmunol.168.11.5954

  43. 43.

    Nagata S Golstein P. The Fas death factor. Science (1995 ) 267(5203):1449–56.

    Not in our library10.1126/science.7533326

  44. 44.

    Van der Bruggen P Traversari C Chomez P Lurquin C De Plaen E Van den Eynde B A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991 ) 254(5038):1643–7.

    Not in our library10.1126/science.1840703

  45. 45.

    Novellino L Castelli C Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2005 ) 54(3):187–207.

    Not in our library10.1007/s00262-004-0560-6

  46. 46.

    Coulie PG Van den Eynde BJ van der Bruggen P Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer (2014 ) 14(2):135–46.

    Not in our library10.1038/nrc3670

  47. 47.

    Schumacher TN Schreiber RD. Neoantigens in cancer immunotherapy. Science (2015 ) 348(6230):69–74.

    Not in our library10.1126/science.aaa4971

  48. 48.

    Snyder A Makarov V Merghoub T Yuan J Zaretsky JM Desrichard A Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014 ) 371(23):2189–99.

    Not in our library10.1056/nejmoa1406498

  49. 49.

    Rizvi NA Hellmann MD Snyder A Kvistborg P Makarov V Havel JJ Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015 ) 348(6230):124–8.

    Not in our library10.1126/science.aaa1348

  50. 50.

    McGranahan N Furness AJ Rosenthal R Ramskov S Lyngaa R Saini SK Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (2016 ) 351(6280):1463–9.

    Not in our library10.1126/science.aaf1490

  51. 51.

    Tran E Turcotte S Gros A Robbins PF Lu YC Dudley ME Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014 ) 344(6184):641–5.

    Not in our library10.1126/science.1251102

  52. 52.

    Lu YC Yao X Crystal JS Li YF El-Gamil M Gross C Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res (2014 ) 20(13):3401–10.

    Not in our library10.1158/1078-0432.ccr-14-0433

  53. 53.

    Stevanovic S Pasetto A Helman SR Gartner JJ Prickett TD Howie B Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science (2017 ) 356(6334):200–5.

    Not in our library10.1126/science.aak9510

  54. 54.

    Pritchard AL Burel JG Neller MA Hayward NK Lopez JA Fatho M Exome sequencing to predict neoantigens in melanoma. Cancer Immunol Res (2015 ) 3(9):992–8.

    Not in our library10.1158/2326-6066.cir-15-0088

  55. 55.

    Carreno BM Magrini V Becker-Hapak M Kaabinejadian S Hundal J Petti AA Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science (2015 ) 348(6236):803–8.

    Not in our library10.1126/science.aaa3828

  56. 56.

    Gueguen M Patard JJ Gaugler B Brasseur F Renauld JC Van Cangh PJ An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol (1998 ) 160(12):6188–94.

    Not in our library

  57. 57.

    Mandruzzato S Brasseur F Andry G Boon T van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med (1997 ) 186(5):785–93.

    Not in our library10.1084/jem.186.5.785

  58. 58.

    Robbins PF El-Gamil M Li YF Kawakami Y Loftus D Appella E A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996 ) 183(3):1185–92.

    Not in our library10.1084/jem.183.3.1185

  59. 59.

    Wolfel T Hauer M Schneider J Serrano M Wolfel C Klehmann-Hieb E A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995 ) 269(5228):1281–4.

    Not in our library10.1126/science.7652577

  60. 60.

    Huang J El-Gamil M Dudley ME Li YF Rosenberg SA Robbins PF T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol (2004 ) 172(10):6057–64.

    Not in our library10.4049/jimmunol.172.10.6057

  61. 61.

    Corbiere V Chapiro J Stroobant V Ma W Lurquin C Lethe B Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011 ) 71(4):1253–62.

    Not in our library10.1158/0008-5472.can-10-2693

  62. 62.

    Lennerz V Fatho M Gentilini C Frye RA Lifke A Ferel D The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005 ) 102(44):16013–8.

    Not in our library10.1073/pnas.0500090102

  63. 63.

    Kawakami Y Wang X Shofuda T Sumimoto H Tupesis J Fitzgerald E Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol (2001 ) 166(4):2871–7.

    Not in our library10.4049/jimmunol.166.4.2871

  64. 64.

    Coulie PG Lehmann F Lethe B Herman J Lurquin C Andrawiss M A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A (1995 ) 92(17):7976–80.

    Not in our library10.1073/pnas.92.17.7976

  65. 65.

    Chiari R Foury F De Plaen E Baurain JF Thonnard J Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res (1999 ) 59(22):5785–92.

    Not in our library

  66. 66.

    Baurain JF Colau D van Baren N Landry C Martelange V Vikkula M High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol (2000 ) 164(11):6057–66.

    Not in our library10.4049/jimmunol.164.11.6057

  67. 67.

    Zorn E Hercend T. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol (1999 ) 29(2):592–601.

    Not in our library10.1002/(sici)1521-4141(199902)29:02<592::aid-immu592>3.0.co;2-2

  68. 68.

    Linard B Bezieau S Benlalam H Labarriere N Guilloux Y Diez E A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol (2002 ) 168(9):4802–8.

    Not in our library10.4049/jimmunol.168.9.4802

  69. 69.

    Vigneron N Ooms A Morel S Degiovanni G Van Den Eynde BJ. Identification of a new peptide recognized by autologous cytolytic T lymphocytes on a human melanoma. Cancer Immun (2002 ) 2:9.

    Not in our library

  70. 70.

    Hogan KT Eisinger DP Cupp SB III Lekstrom KJ Deacon DD Shabanowitz J The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res (1998 ) 58(22):5144–50.

    Not in our library

  71. 71.

    Takenoyama M Baurain JF Yasuda M So T Sugaya M Hanagiri T A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer (2006 ) 118(8):1992–7.

    Not in our library10.1002/ijc.21594

  72. 72.

    Echchakir H Mami-Chouaib F Vergnon I Baurain JF Karanikas V Chouaib S A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res (2001 ) 61(10):4078–83.

    Not in our library

  73. 73.

    Brandle D Brasseur F Weynants P Boon T Van den Eynde B A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med (1996 ) 183(6):2501–8.

    Not in our library10.1084/jem.183.6.2501

  74. 74.

    Gaudin C Kremer F Angevin E Scott V Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol (1999 ) 162(3):1730–8.

    Not in our library

  75. 75.

    Maccalli C Li YF El-Gamil M Rosenberg SA Robbins PF. Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res (2003 ) 63(20):6735–43.

    Not in our library

  76. 76.

    Wang HY Peng G Guo Z Shevach EM Wang RF. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol (2005 ) 174(5):2661–70.

    Not in our library10.4049/jimmunol.174.5.2661

  77. 77.

    Wang RF Wang X Atwood AC Topalian SL Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (1999 ) 284(5418):1351–4.

    Not in our library10.1126/science.284.5418.1351

  78. 78.

    Wang HY Zhou J Zhu K Riker AI Marincola FM Wang RF. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J Exp Med (2002 ) 195(11):1397–406.

    Not in our library10.1084/jem.20020141

  79. 79.

    Wang RF Wang X Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med (1999 ) 189(10):1659–68.

    Not in our library10.1084/jem.189.10.1659

  80. 80.

    Topalian SL Gonzales MI Ward Y Wang X Wang RF. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res (2002 ) 62(19):5505–9.

    Not in our library

  81. 81.

    Novellino L Renkvist N Rini F Mazzocchi A Rivoltini L Greco A Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J Immunol (2003 ) 170(12):6363–70.

    Not in our library10.4049/jimmunol.170.12.6363

  82. 82.

    Pieper R Christian RE Gonzales MI Nishimura MI Gupta G Settlage RE Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med (1999 ) 189(5):757–66.

    Not in our library10.1084/jem.189.5.757

  83. 83.

    Gros A Parkhurst MR Tran E Pasetto A Robbins PF Ilyas S Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med (2016 ) 22(4):433–8.

    Not in our library10.1038/nm.4051

  84. 84.

    Sahin U Derhovanessian E Miller M Kloke BP Simon P Lower M Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature (2017 ) 547(7662):222–6.

    Not in our library10.1038/nature23003

  85. 85.

    Robbins PF Lu YC El-Gamil M Li YF Gross C Gartner J Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013 ) 19(6):747–52.

    Not in our library10.1038/nm.3161

  86. 86.

    Wick DA Webb JR Nielsen JS Martin SD Kroeger DR Milne K Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res (2014 ) 20(5):1125–34.

    Not in our library10.1158/1078-0432.ccr-13-2147

  87. 87.

    Rock KL Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol (1999 ) 17:739–79.

    Not in our library10.1146/annurev.immunol.17.1.739

  88. 88.

    Hammer GE Kanaseki T Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity (2007 ) 26(4):397–406.

    Not in our library10.1016/j.immuni.2007.04.003

  89. 89.

    Marincola FM Jaffee EM Hicklin DJ Ferrone S Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000 ) 74:181–273.

    Not in our library10.1016/s0065-2776(08)60911-6

  90. 90.

    Kessler JH Khan S Seifert U Le Gall S Chow KM Paschen A Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes. Nat Immunol (2011 ) 12(1):45–53.

    Not in our library10.1038/ni.1974

  91. 91.

    Parmentier N Stroobant V Colau D de Diesbach P Morel S Chapiro J Production of an antigenic peptide by insulin-degrading enzyme. Nat Immunol (2010 ) 11(5):449–54.

    Not in our library10.1038/ni.1862

  92. 92.

    Medina F Ramos M Iborra S de Leon P Rodriguez-Castro M Del Val M. Furin-processed antigens targeted to the secretory route elicit functional TAP1-/-CD8+ T lymphocytes in vivo. J Immunol (2009 ) 183(7):4639–47.

    Not in our library10.4049/jimmunol.0901356

  93. 93.

    Van Hall T Wolpert EZ van Veelen P Laban S van der Veer M Roseboom M Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med (2006 ) 12(4):417–24.

    Not in our library10.1038/nm1381

  94. 94.

    El Hage F Stroobant V Vergnon I Baurain JF Echchakir H Lazar V Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway. Proc Natl Acad Sci U S A (2008 ) 105(29):10119–24.

    Not in our library10.1073/pnas.0802753105

  95. 95.

    Durgeau A El Hage F Vergnon I Validire P de Montpreville V Besse B Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J Immunol (2011 ) 187(11):5532–9.

    Not in our library10.4049/jimmunol.1102060

  96. 96.

    Ngoenkam J Schamel WW Pongcharoen S Selected signalling proteins recruited to the T-cell receptor-CD3 complex. Immunology (2017 ) 153(1):42–50.

    Not in our library10.1111/imm.12809

  97. 97.

    Alt FW Oltz EM Young F Gorman J Taccioli G Chen J. VDJ recombination. Immunol Today (1992 ) 13(8):306–14.

    Not in our library10.1016/0167-5699(92)90043-7

  98. 98.

    Davis MM Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature (1988 ) 334(6181):395–402.

    Not in our library10.1038/334395a0

  99. 99.

    Pannetier C Cochet M Darche S Casrouge A Zoller M Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A (1993 ) 90(9):4319–23.

    Not in our library10.1073/pnas.90.9.4319

  100. 100.

    Gorski J Yassai M Zhu X Kissela B Kissella B Keever C Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol (1994 ) 152(10):5109–19.

    Not in our library

  101. 101.

    Xin-Sheng Y Zheng-Jun X Li M Wan-Bang S Wei-Yang Z Qian W Analysis of the CDR3 region of alpha/beta T-cell receptors (TCRs) and TCR BD gene double-stranded recombination signal sequence breaks end in peripheral blood mononuclear cells of T-lineage acute lymphoblastic leukemia. Clin Lab Haematol (2006 ) 28(6):405–15.

    Not in our library10.1111/j.1365-2257.2006.00827.x

  102. 102.

    Wang CY Fang YX Chen GH Jia HJ Zeng S He XB Analysis of the CDR3 length repertoire and the diversity of T cell receptor alpha and beta chains in swine CD4+ and CD8+ T lymphocytes. Mol Med Rep (2017 ) 16(1):75–86.

    Not in our library10.3892/mmr.2016.5981

  103. 103.

    Ria F van den Elzen P Madakamutil LT Miller JE Maverakis E Sercarz EE. Molecular characterization of the T cell repertoire using immunoscope analysis and its possible implementation in clinical practice. Curr Mol Med (2001 ) 1(3):297–304.

    Not in our library10.2174/1566524013363690

  104. 104.

    Even J Lim A Puisieux I Ferradini L Dietrich PY Toubert A T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases. Res Immunol (1995 ) 146(2):65–80.

    Not in our library10.1016/0923-2494(96)80240-9

  105. 105.

    Gaudin C Dietrich PY Robache S Guillard M Escudier B Lacombe MJ In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res (1995 ) 55(3):685–90.

    Not in our library

  106. 106.

    Valteau D Scott V Carcelain G Hartmann O Escudier B Hercend T T-cell receptor repertoire in neuroblastoma patients. Cancer Res (1996 ) 56(2):362–9.

    Not in our library

  107. 107.

    Echchakir H Asselin-Paturel C Dorothee G Vergnon I Grunenwald D Chouaib S Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas. Int J Cancer (1999 ) 81(2):205–13.

    Not in our library10.1002/(sici)1097-0215(19990412)81:2<205::aid-ijc7>3.0.co;2-m

  108. 108.

    Echchakir H Dorothee G Vergnon I Menez J Chouaib S Mami-Chouaib F. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc Natl Acad Sci U S A (2002 ) 99(14):9358–63.

    Not in our library10.1073/pnas.142308199

  109. 109.

    Ingen-Housz-Oro S Bussel A Flageul B Michel L Dubertret L Kourilsky P A prospective study on the evolution of the T-cell repertoire in patients with Sezary syndrome treated by extracorporeal photopheresis. Blood (2002 ) 100(6):2168–74.

    Not in our library

  110. 110.

    Lim A Baron V Ferradini L Bonneville M Kourilsky P Pannetier C. Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses. J Immunol Methods (2002 ) 261(1–2):177–94.

    Not in our library10.1016/s0022-1759(02)00004-2

  111. 111.

    Holt RA Jones SJ. The new paradigm of flow cell sequencing. Genome Res (2008 ) 18(6):839–46.

    Not in our library10.1101/gr.073262.107

  112. 112.

    Shendure J Ji H. Next-generation DNA sequencing. Nat Biotechnol (2008 ) 26(10):1135–45.

    Not in our library10.1038/nbt1486

  113. 113.

    Woodsworth DJ Castellarin M Holt RA. Sequence analysis of T-cell repertoires in health and disease. Genome Med (2013 ) 5(10):98.

    Not in our library10.1186/gm502

  114. 114.

    Freeman JD Warren RL Webb JR Nelson BH Holt RA. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res (2009 ) 19(10):1817–24.

    Not in our library10.1101/gr.092924.109

  115. 115.

    Boria I Cotella D Dianzani I Santoro C Sblattero D. Primer sets for cloning the human repertoire of T cell receptor variable regions. BMC Immunol (2008 ) 9:50.

    Not in our library10.1186/1471-2172-9-50

  116. 116.

    Warren RL Nelson BH Holt RA. Profiling model T-cell metagenomes with short reads. Bioinformatics (2009 ) 25(4):458–64.

    Not in our library10.1093/bioinformatics/btp010

  117. 117.

    Linnemann C Heemskerk B Kvistborg P Kluin RJ Bolotin DA Chen X High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013 ) 19(11):1534–41.

    Not in our library10.1038/nm.3359

  118. 118.

    Brown SD Raeburn LA Holt RA. Profiling tissue-resident T cell repertoires by RNA sequencing. Genome Med (2015 ) 7:125.

    Not in our library10.1186/s13073-015-0248-x

  119. 119.

    Li B Li T Pignon JC Wang B Wang J Shukla SA Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet (2016 ) 48(7):725–32.

    Not in our library10.1038/ng.3581

  120. 120.

    Fang H Yamaguchi R Liu X Daigo Y Yew PY Tanikawa C Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor alpha and beta chains using next-generation sequencing (NGS). Oncoimmunology (2014 ) 3(12):e968467

    Not in our library10.4161/21624011.2014.968467

  121. 121.

    Reuben A Gittelman R Gao J Zhang J Yusko EC Wu CJ TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence. Cancer Discov (2017 ) 7(10):1088–97.

    Not in our library10.1158/2159-8290.cd-17-0256

  122. 122.

    Cha E Klinger M Hou Y Cummings C Ribas A Faham M Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med (2014 ) 6(238):238ra70.

    Not in our library10.1126/scitranslmed.3008211

  123. 123.

    Roh W Chen PL Reuben A Spencer CN Prieto PA Miller JP Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med (2017 ) 9(379):eaah3560

    Not in our library10.1126/scitranslmed.aah3560

  124. 124.

    Tumeh PC Harview CL Yearley JH Shintaku IP Taylor EJ Robert L PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014 ) 515(7528):568–71.

    Not in our library10.1038/nature13954

  125. 125.

    Hodi FS O’Day SJ McDermott DF Weber RW Sosman JA Haanen JB Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010 ) 363(8):711–23.

    Not in our library10.1056/nejmoa1003466

  126. 126.

    Van Allen EM Miao D Schilling B Shukla SA Blank C Zimmer L Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015 ) 350(6257):207–11.

    Not in our library10.1126/science.aad0095

  127. 127.

    Robert C Schachter J Long GV Arance A Grob JJ Mortier L Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med (2015 ) 372(26):2521–32.

    Not in our library10.1056/nejmoa1503093

  128. 128.

    Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012 ) 366(26):2443–54.

    Not in our library10.1056/nejmoa1200690

  129. 129.

    Herbst RS Baas P Kim DW Felip E Perez-Gracia JL Han JY Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (2016 ) 387(10027):1540–50.

    Not in our library10.1016/s0140-6736(15)01281-7

  130. 130.

    Humphries C Adoptive cell therapy: honing that killer instinct. Nature (2013 ) 504(7480):S13–5.

    Not in our library10.1038/504s13a

  131. 131.

    Maus MV Fraietta JA Levine BL Kalos M Zhao Y June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014 ) 32:189–225.

    Not in our library10.1146/annurev-immunol-032713-120136

  132. 132.

    Ott PA Hu Z Keskin DB Shukla SA Sun J Bozym DJ An immunogenic personal neoantigen vaccine for patients with melanoma. Nature (2017 ) 547(7662):217–21.

    Not in our library10.1038/nature22991

  133. 133.

    Lerret NM Marzo AL. Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors. Oncoimmunology (2013 ) 2(2):e22731.

    Not in our library10.4161/onci.22731

  134. 134.

    Dudley ME Wunderlich JR Shelton TE Even J Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003 ) 26(4):332–42.

    Not in our library10.1097/00002371-200307000-00005

  135. 135.

    Dudley ME Wunderlich JR Robbins PF Yang JC Hwu P Schwartzentruber DJ Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002 ) 298(5594):850–4.

    Not in our library10.1126/science.1076514

  136. 136.

    Rosenberg SA Yang JC Sherry RM Kammula US Hughes MS Phan GQ Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011 ) 17(13):4550–7.

    Not in our library10.1158/1078-0432.ccr-11-0116

  137. 137.

    Chandran SS Somerville RPT Yang JC Sherry RM Klebanoff CA Goff SL Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol (2017 ) 18(6):792–802.

    Not in our library10.1016/s1470-2045(17)30251-6

  138. 138.

    Hinrichs CS Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014 ) 257(1):56–71.

    Not in our library10.1111/imr.12132

  139. 139.

    Dudley ME Gross CA Somerville RP Hong Y Schaub NP Rosati SF Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol (2013 ) 31(17):2152–9.

    Not in our library10.1200/jco.2012.46.6441

  140. 140.

    Pasetto A Gros A Robbins PF Deniger DC Prickett TD Matus-Nicodemos R Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol Res (2016 ) 4(9):734–43.

    Not in our library10.1158/2326-6066.cir-16-0001

  141. 141.

    Parkhurst M Gros A Pasetto A Prickett T Crystal JS Robbins P Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin Cancer Res (2017 ) 23(10):2491–505.

    Not in our library10.1158/1078-0432.ccr-16-2680

  142. 142.

    Verdegaal EM de Miranda NF Visser M Harryvan T van Buuren MM Andersen RS Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016 ) 536(7614):91–5.

    Not in our library10.1038/nature18945

  143. 143.

    Baitsch L Baumgaertner P Devevre E Raghav SK Legat A Barba L Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest (2011 ) 121(6):2350–60.

    Not in our library10.1172/jci46102

  144. 144.

    Djenidi F Adam J Goubar A Durgeau A Meurice G de Montpreville V CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol (2015 ) 194(7):3475–86.

    Not in our library10.4049/jimmunol.1402711

  145. 145.

    Lanitis E Dangaj D Irving M Coukos G. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol (2017 ) 28(suppl_12):xii18–32.

    Not in our library10.1093/annonc/mdx238

  146. 146.
    Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells · 2013
    No notice
  147. 147.

    June CH. Remote controlled CARs: towards a safer therapy for leukemia. Cancer Immunol Res (2016 ) 4(8):643.

    Not in our library10.1158/2326-6066.cir-16-0132

  148. 148.

    Berry LJ Moeller M Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens (2009 ) 74(4):277–89.

    Not in our library10.1111/j.1399-0039.2009.01336.x

  149. 149.

    Atanackovic D Radhakrishnan SV Bhardwaj N Luetkens T. Chimeric antigen receptor (CAR) therapy for multiple myeloma. Br J Haematol (2016 ) 172(5):685–98.

    Not in our library10.1111/bjh.13889

  150. 150.

    Rosenberg SA Cell transfer immunotherapy for metastatic solid cancer – what clinicians need to know. Nat Rev Clin Oncol (2011 ) 8(10):577–85.

    Not in our library10.1038/nrclinonc.2011.116

  151. 151.

    Ray S Chhabra A Chakraborty NG Hegde U Dorsky DI Chodon T MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol (2010 ) 136(3):338–47.

    Not in our library10.1016/j.clim.2010.04.013

  152. 152.

    Sadelain M Riviere I Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer (2003 ) 3(1):35–45.

    Not in our library10.1038/nrc971

  153. 153.

    Robbins PF Morgan RA Feldman SA Yang JC Sherry RM Dudley ME Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011 ) 29(7):917–24.

    Not in our library10.1200/jco.2010.32.2537

  154. 154.

    Irving M Zoete V Hebeisen M Schmid D Baumgartner P Guillaume P Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem (2012 ) 287(27):23068–78.

    Not in our library10.1074/jbc.m112.357673

  155. 155.

    Morgan RA Dudley ME Wunderlich JR Hughes MS Yang JC Sherry RM Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006 ) 314(5796):126–9.

    Not in our library10.1126/science.1129003

  156. 156.

    Johnson LA Morgan RA Dudley ME Cassard L Yang JC Hughes MS Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009 ) 114(3):535–46.

    Not in our library10.1182/blood-2009-03-211714

  157. 157.

    Kochenderfer JN Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013 ) 10(5):267–76.

    Not in our library10.1038/nrclinonc.2013.46

  158. 158.

    Brentjens RJ Riviere I Park JH Davila ML Wang X Stefanski J Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood (2011 ) 118(18):4817–28.

    Not in our library10.1182/blood-2011-04-348540

  159. 159.

    Kalos M Levine BL Porter DL Katz S Grupp SA Bagg A T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011 ) 3(95):95ra73.

    Not in our library10.1126/scitranslmed.3002842

  160. 160.

    Brentjens RJ Davila ML Riviere I Park J Wang X Cowell LG CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013 ) 5(177):177ra38.

    Not in our library10.1126/scitranslmed.3005930

  161. 161.

    Maude SL Frey N Shaw PA Aplenc R Barrett DM Bunin NJ Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014 ) 371(16):1507–17.

    Not in our library10.1056/nejmoa1407222

  162. 162.

    Lee DW Kochenderfer JN Stetler-Stevenson M Cui YK Delbrook C Feldman SA T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet (2015 ) 385(9967):517–28.

    Not in our library10.1016/s0140-6736(14)61403-3

  163. 163.

    Beatty GL Haas AR Maus MV Torigian DA Soulen MC Plesa G Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res (2014 ) 2(2):112–20.

    Not in our library10.1158/2326-6066.cir-13-0170

  164. 164.

    Pardoll DM The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012 ) 12(4):252–64.

    Not in our library10.1038/nrc3239

  165. 165.

    Sharma P Allison JP. The future of immune checkpoint therapy. Science (2015 ) 348(6230):56–61.

    Not in our library10.1126/science.aaa8172

  166. 166.

    Topalian SL Wolchok JD Chan TA Mellman I Palucka K Banchereau J Immunotherapy: the path to win the war on cancer? Cell (2015 ) 161(2):185–6.

    Not in our library10.1016/j.cell.2015.03.045

  167. 167.

    Im SJ Hashimoto M Gerner MY Lee J Kissick HT Burger MC Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature (2016 ) 537(7620):417–21.

    Not in our library10.1038/nature19330

  168. 168.

    Wherry EJ. T cell exhaustion. Nat Immunol (2011 ) 12(6):492–9.

    Not in our library10.1038/ni.2035

  169. 169.

    Larkin J Chiarion-Sileni V Gonzalez R Grob JJ Cowey CL Lao CD Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med (2015 ) 373(1):23–34.

    Not in our library10.1056/nejmoa1504030

  170. 170.

    Sakuishi K Apetoh L Sullivan JM Blazar BR Kuchroo VK Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010 ) 207(10):2187–94.

    Not in our library10.1084/jem.20100643

  171. 171.

    Melero I Grimaldi AM Perez-Gracia JL Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013 ) 19(5):997–1008.

    Not in our library10.1158/1078-0432.ccr-12-2214

  172. 172.

    Dai M Yip YY Hellstrom I Hellstrom KE. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res (2015 ) 21(5):1127–38.

    Not in our library10.1158/1078-0432.ccr-14-1339

  173. 173.

    Kvistborg P Philips D Kelderman S Hageman L Ottensmeier C Joseph-Pietras D Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med (2014 ) 6(254):254ra128.

    Not in our library10.1126/scitranslmed.3008918

  174. 174.

    Luksza M Riaz N Makarov V Balachandran VP Hellmann MD Solovyov A A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature (2017 ) 551(7681):517–20.

    Not in our library10.1038/nature24473

  175. 175.

    Gilboa E The makings of a tumor rejection antigen. Immunity (1999 ) 11(3):263–70.

    Not in our library10.1016/s1074-7613(00)80101-6

  176. 176.

    Zaretsky JM Garcia-Diaz A Shin DS Escuin-Ordinas H Hugo W Hu-Lieskovan S Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med (2016 ) 375(9):819–29.

    Not in our library10.1056/nejmoa1604958

  177. 177.

    Shin DS Zaretsky JM Escuin-Ordinas H Garcia-Diaz A Hu-Lieskovan S Kalbasi A Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov (2017 ) 7(2):188–201.

    Not in our library10.1158/2159-8290.cd-16-1223

  178. 178.

    Gao J Shi LZ Zhao H Chen J Xiong L He Q Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell (2016 ) 167(2):397–404.e9.

    Not in our library10.1016/j.cell.2016.08.069

  179. 179.

    Palucka K Banchereau J Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012 ) 12(4):265–77.

    Not in our library10.1038/nrc3258

  180. 180.

    Finn OJ. Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol Res (2017 ) 5(5):347–54.

    Not in our library10.1158/2326-6066.cir-17-0112

  181. 181.

    Parmiani G Castelli C Dalerba P Mortarini R Rivoltini L Marincola FM Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002 ) 94(11):805–18.

    Not in our library10.1093/jnci/94.11.805

  182. 182.

    Miller MJ Foy KC Kaumaya PT. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med (2013 ) 15(82):166–76.

    Not in our library

  183. 183.

    Boon T Coulie PG Van den Eynde BJ van der Bruggen P Human T cell responses against melanoma. Annu Rev Immunol (2006 ) 24:175–208.

    Not in our library10.1146/annurev.immunol.24.021605.090733

  184. 184.

    Rosenberg SA Yang JC Schwartzentruber DJ Hwu P Marincola FM Topalian SL Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998 ) 4(3):321–7.

    Not in our library10.1038/nm0398-321

  185. 185.

    Speiser DE Baumgaertner P Voelter V Devevre E Barbey C Rufer N Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008 ) 105(10):3849–54.

    Not in our library10.1073/pnas.0800080105

  186. 186.

    Quakkelaar ED Melief CJ. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv Immunol (2012 ) 114:77–106.

    Not in our library10.1016/b978-0-12-396548-6.00004-4

  187. 187.

    Melief CJ van Hall T Arens R Ossendorp F van der Burg SH. Therapeutic cancer vaccines. J Clin Invest (2015 ) 125(9):3401–12.

    Not in our library10.1172/jci80009

  188. 188.

    Rosenberg SA Yang JC Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004 ) 10(9):909–15.

    Not in our library10.1038/nm1100

  189. 189.

    Klebanoff CA Acquavella N Yu Z Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011 ) 239(1):27–44.

    Not in our library10.1111/j.1600-065x.2010.00979.x

  190. 190.

    Robbins PF Kassim SH Tran TL Crystal JS Morgan RA Feldman SA A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res (2015 ) 21(5):1019–27.

    Not in our library10.1158/1078-0432.ccr-14-2708

  191. 191.

    van der Burg SH Arens R Ossendorp F van Hall T Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016 ) 16(4):219–33.

    Not in our library10.1038/nrc.2016.16

  192. 192.

    Heemskerk B Kvistborg P Schumacher TN. The cancer antigenome. EMBO J (2013 ) 32(2):194–203.

    Not in our library10.1038/emboj.2012.333

  193. 193.

    Tran E Robbins PF Rosenberg SA. ’Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol (2017 ) 18(3):255–62.

    Not in our library10.1038/ni.3682

  194. 194.

    Oliveira CC Querido B Sluijter M de Groot AF van der Zee R Rabelink MJ New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation. J Immunol (2013 ) 191(8):4020–8.

    Not in our library10.4049/jimmunol.1301496

  195. 195.

    Doorduijn EM Sluijter M Querido BJ Oliveira CC Achour A Ossendorp F TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. J Clin Invest (2016 ) 126(2):784–94.

    Not in our library10.1172/jci83671

  196. 196.

    Butterfield LH. Cancer vaccines. BMJ (2015 ) 350:h988.

    Not in our library10.1136/bmj.h988

Cited by papers we hold 12

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.